Neuroimaging research in human MDMA users: A review

Psychopharmacology

Volumn 189, Issue 4, 2007, Pages 539-556

  Cowan, Ronald L ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

3,4 Methylenedioxymethamphetamine; Drug abuse; Drug toxicity; Ecstasy; fMRI; MDMA; Neuroimaging; PET; SPECT

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; RECREATIONAL DRUG; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER;

BRAIN FUNCTION; BRAIN SIZE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEST RETEST RELIABILITY; WORKING MEMORY;

AMPHETAMINE-RELATED DISORDERS; ASPARTIC ACID; ATTENTION; BIOMEDICAL RESEARCH; BRAIN; CEREBROVASCULAR CIRCULATION; HUMANS; INOSITOL; MEMORY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, SEROTONIN, 5-HT2A; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SEROTONIN; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33751232336     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0467-3     Document Type: Review

References (115)

1. ABC Television Network (2004) Primetime special: Peter Jennings - Ecstasy rising. April 1
2. Aguirre N, Barrionuevo M, Ramirez MJ, Del RJ, Lasheras B (1999) Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. Neuroreport 10:3675-3680
3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington, DC
4. Ashburner J, Friston KJ (2000) Voxel-based morphometry - the methods. Neuroimage 11:805-821
5. Azmitia EC (2002) Cajal's hypotheses on neurobiones and neurotropic factor match properties of microtubules and S-100 beta. Prog Brain Res 136:87-100
6. Bankson MG, Cunningham KA (2001) 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 297:846-852
7. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB (1996) Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 7:1397-1400
8. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A (2002) Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 22:6766-6772
9. Bhakoo KK, Pearce D (2000) In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 74:254-262
10. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J, Bruck W (1999) Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 20:1619-1627
11. Buchert R, Obrocki J, Thomasius R, Vaterlein O, Petersen K, Jenicke L, Bohuslavizki KH, Clausen M (2001) Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET. Nucl Med Commun 22:889-897
12. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M (2003) Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med 44:375-384
13. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M (2004) A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am J Psychiatry 161:1181-1189
14. Chang L, Ernst T, Grob CS, Poland RE (1999) Cerebral (1)H MRS alterations in recreational 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy") users. J Magn Reson Imaging 10:521-526
15. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE (2000) Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res 98:15-28
16. Chang L, Speck O, Miller EN, Braun J, Jovicich J, Koch C, Itti L, Ernst T (2001) Neural correlates of attention and working memory deficits in HIV patients. Neurology 57:1001-1007
17. Check E (2004) The ups and downs of Ecstasy. Nature 429:126-128
18. Cohen Z, Bonvento G, Lacombe P, Hamel E (1996) Serotonin in the regulation of brain microcirculation. Prog Neurobiol 50:335-362
19. Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA (2002) The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97:1531-1536
20. Cowan RL, Lyoo IK, Sung SM, Ahn KH, Kim MJ, Hwang J, Haga E, Vimal RL, Lukas SE, Renshaw PF (2003) Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. Drug Alcohol Depend 72:225-235
21. Crittenden J (2005) Harvard doc's study: dying with ecstasy. The Boston Herald. January 7
22. Daumann J, Schnitker R, Weidemann J, Schnell K, Thron A, Gouzoulis-Mayfrank E (2003a) Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users. Neuroreport 14:1983-1987
23. Daumann J, Fimm B, Willmes K, Thron A, Gouzoulis-Mayfrank E (2003b) Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study. Brain Res Cogn Brain Res 16:479-487
24. Daumann J Jr, Fischermann T, Heekeren K, Thron A, Gouzoulis-Mayfrank E (2004a) Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study. Biol Psychiatry 56:349-355
25. Daumann J, Fischermann T, Pilatus U, Thron A, Moeller-Hartmann W, Gouzoulis-Mayfrank E (2004b) Proton magnetic resonance spectroscopy in ecstasy (MDMA) users. Neurosci Lett 362:113-116
26. Daumann J, Fischermann T, Heekeren K, Henke K, Thron A, Gouzoulis-Mayfrank E (2005) Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology (Berl) 180:607-611
27. de Almeida SP, Silva MT (2003) Ecstasy (MDMA): effects and patterns of use reported by users in Sao Paulo. Rev Bras Psiquiatr 25:11-17
28. de la Torre R, Farre M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25:505-508
29. de Win MM, de Jeu RA, De BK, Habraken JB, Reneman L, Booij J, den Heeten GJ (2004) Validity of in vivo [123I]beta-CIT SPECT in detecting MDMA-induced neurotoxicity in rats. Eur Neuropsychopharmacol 14:185-189
30. de Stefano N, Matthews PM, Arnold DL (1995) Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 34:721-727
31. Doblin R (2002) A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. J Psychoactive Drugs 34:185-194
32. Duman RS, Malberg J, Nakagawa S, D'Sa C (2000) Neuronal plasticity and survival in mood disorders. Biol Psychiatry 48:732-739
33. Ernst T, Chang L, Jovicich J, Ames N, Arnold S (2002) Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 59:1343-1349
34. European Monitoring Centre for Drugs and Drug Addiction (2005) News Release No. 9: cocaine, amphetamines, Ecstasy, and cannabis: latest trends. November 24, LISBON
35. Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte GA, Woods JH, Winger G (2004) Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 29:1270-1281
36. Fiorella D, Helsley S, Lorrain DS, Rabin RA, Winter JC (1995) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. III: The mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion. Psychopharmacology (Berl) 121:364-372
37. Frankle WG, Huang Y, Hwang DR, Talbot PS, Slifstein M, Van HR, bi-Dargham A, Laruelle M (2004) Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med 45:682-694
38. Gamma A, Buck A, Berthold T, Vollenweider FX (2001) No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [H2(15)O]-positron emission tomography study. J Clin Psychopharmacol 21:66-71
39. Gray JA, Roth BL (2001) Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56:441-451
40. Green AR (2004) MDMA: fact and fallacy, and the need to increase knowledge in both the scientific and popular press. Psychopharmacology (Berl) 173:231-233
41. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508
42. Gross SR, Barrett SP, Shestowsky JS, Pihl RO (2002) Ecstasy and drug consumption patterns: a Canadian rave population study. Can J Psychiatry 47:546-551
43. Guimaraes AR, Schwartz P, Prakash MR, Carr CA, Berger UV, Jenkins BG, Coyle JT, Gonzalez RG (1995) Quantitative in vivo 1H nuclear magnetic resonance spectroscopic imaging of neuronal loss in rat brain. Neuroscience 69:1095-1101
44. Gujar SK, Maheshwari S, Bjorkman-Burtscher I, Sundgren PC (2005) Magnetic resonance spectroscopy. J Neuroophthalmol 25:217-226
45. Horschitz S, Hummerich R, Schloss P (2001) Down-regulation of the rat serotonin transporter upon exposure to a selective serotonin reuptake inhibitor. Neuroreport 12:2181-2184
46. Hurley RA, Reneman L, Taber KH (2002) Ecstasy in the brain: a model for neuroimaging. J Neuropsychiatry Clin Neurosci 14:125-129
47. Irvine RJ, Keane M, Felgate P, McCann UD, Callaghan PD, White JM (2006) Plasma drug concentrations and physiological measures in 'Dance Party' participants. Neuropsychopharmacology 31 (2):424-430
48. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH (2004) Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology (Berl) 173:383-390
49. Jung RE, Yeo RA, Chiulli SJ, Sibbitt WL Jr, Weers DC, Hart BL, Brooks WM (1999) Biochemical markers of cognition: a proton MR spectroscopy study of normal human brain. Neuroreport 10:3327-3331
50. Kalra S, Cashman NR, Genge A, Arnold DL (1998) Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 9:1757-1761
51. Kish SJ (2002) How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 71:845-855
52. Kohn D (2004) Ecstasy research looks for benefits: advocates explore use of drug, illegal since 1985, to treat emotional wounds. Baltimore Sun. July 25
53. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531
54. Lieberman JA, Aghajanian GK (1999) Caveat emptor: researcher beware. Neuropsychopharmacology 21:471-473
55. Lyles J, Cadet JL (2003) Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res Brain Res Rev 42:155-168
56. Marsa L (2005) Ecstasy's good side: The much maligned drug may ease the anxieties of the terminally ill. LA Times. April 11
57. McCann UD, Ricaurte GA (2001) Caveat emptor: editors beware. Neuropsychopharmacology 24:333-336
58. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352:1433-1437
59. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA (2005) Quantitative PET studies of the serotonin transporter in MDMA users and controls using [(11)C]McN5652 and [(11)C]DASB. Neuropsychopharmacology 30:1741-1750
60. McGregor IS, Clemens KJ, Van der PG, Li KM, Hunt GE, Chen F, Lawrence AJ (2003) Increased anxiety 3 months after brief exposure to MDMA ("Ecstasy") in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 28:1472-1484
61. Miner LH, Schroeter S, Blakely RD, Sesack SR (2000) Ultrastructural localization of the serotonin transporter in superficial and deep layers of the rat prelimbic prefrontal cortex and its spatial relationship to dopamine terminals. J Comp Neurol 427:220-234
62. Moeller FG, Steinberg JL, Dougherty DM, Narayana PA, Kramer LA, Renshaw PF (2004) Functional MRI study of working memory in MDMA users. Psychopharmacology (Berl) 177:185-194
63. Montoya AG, Sorrentino R, Lukas SE, Price BH (2002) Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review. Harv Rev Psychiatry 10:212-220
64. Morgan MJ (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 152:230-248
65. Morton J (2005) Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 5:79-86
66. Moses-Kolko EL, Berga SL, Greer PJ, Smith G, Cidis MC, Drevets WC (2003) Widespread increases of cortical serotonin type 2A receptor availability after hormone therapy in euthymic postmenopausal women. Fertil Steril 80:554-559
67. Nair SG, Gudelsky GA (2006) 3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat. Psychopharmacology (Berl) 184(2):182-189
68. National Drug Intelligence Center (2005) National drug threat assessment 2005 summary report. February (2005-Q0317-005)
69. Newton C (2001) FDA OKs clinical testing of Ecstasy. The Washington Post. November 6
70. O'Hearn E, Battaglia G, de Souza EB, Kuhar MJ, Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8:2788-2803
71. Obergriesser T, Ende G, Braus DF, Henn FA (2001) Hippocampal 1H-MRSI in ecstasy users. Eur Arch Psychiatry Clin Neurosci 251:114-116
72. Obrocki J, Buchert R, Vaterlein O, Thomasius R, Beyer W, Schiemann T (1999) Ecstasy-long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 175:186-188
73. Obrocki J, Schmoldt A, Buchert R, Andresen B, Petersen K, Thomasius R (2002) Specific neurotoxicity of chronic use of ecstasy. Toxicol Lett 127:285-297
74. Parker GJ (2004) Analysis of MR diffusion weighted images. Br J Radiol 77:S176-S185
75. Parrott AC (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16(8):557-577
76. Parrott AC (2004) Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl) 173:234-241
77. Patel TB, Clark JB (1979) Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 184:539-546
78. Pedersen W, Skrondal A (1999) Ecstasy and new patterns of drug use: a normal population study. Addiction 94:1695-1706
79. Pubill D, Canudas AM, Pallas M, Camins A, Camarasa J, Escubedo E (2003) Different glial response to methamphetamine- and methylenedioxymethamphetamine- induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 367:490-499
80. Reneman L, Booij J, Schmand B, van den BW, Gunning B (2000a) Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology (Berl) 148:322-324
81. Reneman L, Habraken JB, Majoie CB, Booij J, den Heeten GJ (2000b) MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. AJNR Am J Neuroradiol 21:1001-1007
82. Reneman L, Booij J, De BK, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den BW (2001a) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358:1864-1869
83. Reneman L, Booij J, Majoie CB, van den BW, den Heeten GJ (2001b) Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach. Hum Psychopharmacol 16:579-588
84. Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den BW, den Heeten GJ, Booij J (2001c) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. Arch Gen Psychiatry 58:901-906
85. Reneman L, Majoie CB, Schmand B, van den BW, den Heeten GJ (2001d) Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report. Biol Psychiatry 50:550-554
86. Reneman L, Majoie CB, Habraken JB, den Heeten GJ (2001e) Effects of ecstasy (MDMA) on the brain in abstinent users: initial observations with diffusion and perfusion MR imaging. Radiology 220:611-617
87. Reneman L, Booij J, Habraken JB, De BK, Hatzidimitriou G, den Heeten GJ, Ricaurte GA (2002a) Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse 46:199-205
88. Reneman L, Booij J, Lavalaye J, De BK, Reitsma JB, Gunning B, den Heeten GJ, van den BW (2002b) Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]beta-CIT SPECT study - preliminary report. Psychopharmacology (Berl) 159:335-340
89. Reneman L, Endert E, De BK, Lavalaye J, Feenstra MG, de Wolff FA, Booij J (2002c) The acute and chronic effects of MDMA ("ecstasy") on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 26:387-396
90. Reneman L, Majoie CB, Flick H, den Heeten GJ (2002d) Reduced N-acetylaspartate levels in the frontal cortex of 3,4- methylenedioxymethamphetamine (Ecstasy) users: preliminary results. AJNR Am J Neuroradiol 23:231-237
91. Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ (2006) Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol 20:164-175
92. Ricaurte GA, DeLanney LE, Irwin I, Langston JW (1988) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 446:165-168
93. Ricaurte GA, Yuan J, McCann UD (2000) (±)3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42:5-10
94. Rojas R, Riascos R, Vargas D, Cuellar H, Borne J (2005) Neuroimaging in drug and substance abuse Part I: cocaine, cannabis, and ecstasy. Top Magn Reson Imaging 16:231-238
95. Ross BD, Danielsen ER, Bluml S (1996) Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy? Dig Dis 14(Suppl 1):30-39
96. Rumpel H, Lim WE, Chang HM, Chan LL, Ho GL, Wong MC, Tan KP (2003) Is myo-inositol a measure of glial swelling after stroke? A magnetic resonance study. J Magn Reson Imaging 17:11-19
97. Sager TN, Thomsen C, Valsborg JS, Laursen H, Hansen AJ (1999) Astroglia contain a specific transport mechanism for N-acetyl-L-aspartate. J Neurochem 73:807-811
98. Scheffel U, Lever JR, Stathis M, Ricaurte GA (1992) Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors. Neuropharmacology 31:881-893
99. Schifano F, Di FL, Forza G, Minicuci N, Bricolo R (1998) MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 52:85-90
100. Schmued LC (2003) Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res 974:127-133
101. Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J (2004) Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. Addict Behav 29:743-752
102. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 175:63-69
103. Simantov R (2004) Multiple molecular and neuropharmacological effects of MDMA (Ecstasy). Life Sci 74:803-814
104. Stoll AL, Renshaw PF, Yurgelun-Todd DA, Cohen BM (2000) Neuroimaging in bipolar disorder: what have we learned? Biol Psychiatry 48:505-517
105. Tanner-Smith EE (2006) Pharmacological content of tablets sold as "ecstasy": results from an online testing service. Drug Alcohol Depend 83(3):247-254
106. The Partnership for a Drug-Free America (2003) PATS study 2003-teens: teen Ecstasy use leveling off after steep increase, but majority still see scan risk in experimenting with "X". February 10
107. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) 167:85-96
108. Turecki G, Briere R, Dewar K, Antonetti T, Lesage AD, Seguin M, Chawky N, Vanier C, Alda M, Joober R, Benkelfat C, Rouleau GA (1999) Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 156:1456-1458
109. Van Oekelen D, Luyten WH, Leysen JE (2003) 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 72:2429-2449
110. Varnas K, Halldin C, Hall H (2004) Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 22:246-260
111. Verrico CD, Miller GM, Madras BK (2005) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 1-15
112. Wang X, Baumann MH, Xu H, Rothman RB (2004) 3,4- methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 53:240-248
113. Wang X, Baumann MH, Xu H, Morales M, Rothman RB (2005) (±)-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. J Pharmacol Exp Ther 314:1002-1012
114. Yamamoto M, Suhara T, Okubo Y, Ichimiya T, Sudo Y, Inoue M, Takano A, Yasuno F, Yoshikawa K, Tanada S (2002) Age-related decline of serotonin transporters in living human brain of healthy males. Life Sci 71:751-757
115. Zhou FC, Tao-Cheng JH, Segu L, Patel T, Wang Y (1998) Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res 805:241-254